Xeno Biosciences is a biotechnology company that provides novel class of treatments for metabolic diseases.
Xeno Biosciences operates as a biopharmaceutical company pioneering a novel class of therapeutics to address large unmet needs in metabolic diseases. Lead program, XEN-101, is a first-in-class, oral formulation designed to shift the gut microbiome to the weight-loss associated state induced by Roux-en-Y Gastric Bypass (RYGB) surgery.It was founded in 2015 and is headquartered in Somerville, Massachusetts.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 8, 2021 | Series A | $7.25M | 4 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Dirigo Angels | — | Series A |
Bangor Angels | — | Series A |
Zhi Gao Holding | — | Series A |
Keiretsu Forum | — | Series A |